pharma · Eosinophilic esophagitis · Narcolepsy
Bioprojet
Bioprojet Pharma
Bioprojet clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 9 rue Rameau, Paris, 75002, FR
- Employees
- 166
- Programs
- 11
- Drugs
- 19
- Patents
- 9
Bioprojet projects
6 ClinicalTrials.gov programs sponsored by Bioprojet.
Bioprojet has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
BP1.4979 / P24-01
Bioprojet Pharma
Binge eating disorder
1 trial -
P22-03
Bioprojet Pharma
Eosinophilic esophagitis
1 trial -
P23-01
Bioprojet Pharma
Anaphylaxis
1 trial -
P24-03
Bioprojet Pharma
Narcolepsy, Narcolepsy with cataplexy
1 trial -
P24-06
Bioprojet Pharma
Narcolepsy
1 trial -
P25-01
Bioprojet Pharma
narcolepsy with cataplexy, Narcolepsy
1 trial
Frequently asked questions
How many clinical projects does Bioprojet have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.